Health&Beauty- Page 104

The FINANCIAL -- New long-term data for Gilenya, the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment.

The FINANCIAL -- While public health care policy and the factors that influence consumer preference and purchasing decisions about health insurance are rapidly shifting, the 2012 Harris Poll EquiTrend(EQ) study finds that brand equity remains strong among the top-ranked health insurers.

The FINANCIAL -- The Associate Safety and Health Manager (ASHM) is a designation administered by the Institute for Safety and Health Management. 

The FINANCIAL -- Sanofi announced abstracts spanning the company’s innovative marketed and late-stage development compounds will be featured at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago, Ill., June 1-5. Sanofi products are noted in more than 170 abstracts

The FINANCIAL -- Arena Pharmaceuticals and Eisai Inc. announced the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc.

The FINANCIAL -- Bayer MaterialScience plans to establish a global wind energy competence and development center at its existing site in Otterup, Denmark.

The FINANCIAL -- Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline.

The FINANCIAL -- Pfizer announced that it has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet.

The FINANCIAL -- Results of the largest Phase III study of acromegaly patients show the novel therapy pasireotide long-acting release (LAR), was significantly more effective at inducing full biochemical control compared to the current standard medical therapy, Sandostatin LAR.

The FINANCIAL -- Georgian doctors and GM Pharmaceuticals were summarizing the results of surveys and studies  on GMP medicines during the special forum last week.